Randomised phase III trial of paclitaxel plus carboplatin (TC) therapy versus irinotecan plus cisplatin (CPT-P) therapy as a first line chemotherapy for clear cell carcinoma of the ovary.

Trial Profile

Randomised phase III trial of paclitaxel plus carboplatin (TC) therapy versus irinotecan plus cisplatin (CPT-P) therapy as a first line chemotherapy for clear cell carcinoma of the ovary.

Completed
Phase of Trial: Phase III

Latest Information Update: 15 Mar 2017

At a glance

  • Drugs Cisplatin (Primary) ; Irinotecan (Primary) ; Carboplatin; Paclitaxel
  • Indications Fallopian tube cancer; Ovarian cancer
  • Focus Registrational; Therapeutic Use
  • Acronyms CCC-1; GCIG; JGOG 3017
  • Most Recent Events

    • 07 Jan 2014 Planned number of patients changed from 662 to 652 as reported in ISRCTN: Current Controlled Trials & European Clinical Trials Database records.
    • 27 Jun 2012 Additional lead trial centre identified as reported by EudraCT.
    • 27 Jul 2011 Actual end date (31 Dec 2010) added as reported by as reported by ISRCTN: Current Controlled Trials.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top